

NNSA Mo-99 Stakeholders Meeting
Crystal City Marriott, Salon D (Potomac) 1999
Jefferson Davis Hwy, Arlington, VA 22202

Wednesday, May 16, 2018 2:00pm – 5:00pm

Welcome and Introductions

NNSA Mo-99 Program Update – Jeff Chamberlin, NNSA Office of Conversion

Section 1 Current U.S. Mo-99 Supply Status – Industry Perspectives

- 1.1 **Mo-99 Supply Updates** - Lantheus Medical Imaging – *Ira Goldman*
- 1.2 **Current Supply Status** - Curium Pharma – *Roy Brown*
- 1.3 Cardinal Health – David Pelliciarini
- 1.4 **NTP Processing Suspension UPPI Experience** - UPPI – John Witkowski via telephone
- 1.5 GE Healthcare – Megha Shah via telephone

Section 2 Conversion updates

- 2.1 **IRE LEU Conversion Update** - Institute for Radioelements – *Valery Host via telephone*

Section 3 USG Updates

- 3.1 **Update on Licensing Reviews Supporting Domestic Molybdenum-99 Production** - NRC – Steven Lynch
- 3.2 FDA – Eric Duffy
- 3.3 **NNSA Mo-99 Program Update** - DOE/NNSA Mo-99 – *Pete Karcz*
 - 3.3.1 Program and budget update
 - 3.3.2 Plans for using increased Laboratory funds
 - 3.3.3 Plans for issuing Funding Opportunity Announcement

Section 4 U.S. Cooperative Agreement Partner Updates

- 4.1 SHINE – Katrina Pitas
- 4.2 NorthStar – *Jim Harvey*

Section 5 Producer and Stakeholder Updates

- 5.1 **Northwest Medical Isotopes, LLC** - Northwest Medical Isotopes – *Carolyn Haass*
- 5.2 **Leadership Presentation at Mo-99 Stakeholders Meeting** - Coqui Radiopharmaceuticals – *Carmen Bigles*
- 5.3 **Niowave’s Domestic Production of Mo-99 from LEU without a Nuclear Reactor** - Niowave – Terry Grimm
- 5.4 Other updates or remarks – *Open*

Section 6 Open Floor and Discussion

Adjourn